Herceptin May Benefit Some Women With Early Breast Cancer
Drug-chemo combo yields low rate of recurrence after three years, study says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 8, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Potential Practice Change in Small HER2-+ Breast CancersPotential Practice Change in Small HER2-+ Breast Cancers
Less intensive chemotherapy combined with trastuzumab resulted in a very high rate of disease-free survival and suggests that more chemo is not needed in stage I disease treated with systemic therapy. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 7, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Herceptin May Benefit Some Women with Early Breast Cancer
Drug-chemo combo yields low rate of recurrence after three years, study saysSource: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 7, 2015 Category: Consumer Health News Source Type: news

Newest HER2-Targeted Therapy No Better Than Original AgentNewest HER2-Targeted Therapy No Better Than Original Agent
Top-line results from the MARIANNE trial show that the latest HER-targeted agent T-DM1 is no better than the original, trastuzumab Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Media News)
Source: Roche Media News - December 19, 2014 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 19, 2014 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Media News)
Source: Roche Media News - December 19, 2014 Category: Pharmaceuticals Source Type: news

Everolimus Does Not Overcome Trastuzumab ResistanceEverolimus Does Not Overcome Trastuzumab Resistance
Inhibiting the PI3K/mTOR pathway did not improve progression-free survival when added to chemotherapy and trastuzumab in women with advanced breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Herceptin found to improve long-term survival of HER2-positive breast cancer patients
(Virginia Commonwealth University) VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 15, 2014 Category: Cancer & Oncology Source Type: news

Herceptin May Be of Little Use in Immune Cell-Heavy Breast Ca
(MedPage Today) -- No impact on recurrence-free survival with trastuzumab plus chemo. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 11, 2014 Category: Journals (General) Source Type: news

Breast Cancer With High TIL Levels: Skip the Trastuzumab?Breast Cancer With High TIL Levels: Skip the Trastuzumab?
A provocative study suggests that HER2 breast cancer patients with high levels of stromal tumor infiltrating lymphocytes may not need trastuzumab (Herceptin). Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
Dateline City: SAN ANTONIO Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER...
Source: Merck.com - Research and Development News - December 10, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news

Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer
(Mayo Clinic) A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker -- the quantity of tumor-infiltrating lymphocytes in a biopsy -- appears irrelevant when trastuzumab is used. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2014 Category: Cancer & Oncology Source Type: news

Data published on ANG4043, anti-HER2 monoclonal antibody for treatment of brain metastases
(The Yates Network) Data published in Molecular Cancer Therapeutics, entitled 'ANG4043, a Novel Brain-penetrant Peptide-mAb Conjugate, is Efficacious against HER2-positive Intracranial Tumors in Mice,' demonstrates that ANG4043, a peptide-monoclonal antibody conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. The antibody is directed against HER2, which is the protein targeted by Herceptin. The data published shows that this technology to cross the blood brain barrier is applicable to biologics such as mAbs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2014 Category: Cancer & Oncology Source Type: news

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - December 8, 2014 Category: Hospital Management Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
Adding intravenous trastuzumab to carboplatin - paclitaxel increased progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Government panel moots clinical trial waiver for two cancer drugs
The two medicines - Aflibercept and Trastuzumab emtansine - are used in treatment of metastatic colorectal cancer and metastatic breast cancer respectively. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 7, 2014 Category: Pharmaceuticals Source Type: news

Should PIK3CA Inform Therapy Choice in Breast Cancer?Should PIK3CA Inform Therapy Choice in Breast Cancer?
Dr Lidia Schapira reports on a study showing that PIK3CA mutations may indicate trastuzumab resistance in HER2+ breast cancer but cautions use of the biomarker as a basis for clinical decisions. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Herceptin Boosts Survival for Breast Cancer, Study Reports
Title: Herceptin Boosts Survival for Breast Cancer, Study ReportsCategory: Health NewsCreated: 10/20/2014 12:00:00 AMLast Editorial Review: 10/21/2014 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 21, 2014 Category: Cancer & Oncology Source Type: news

Herceptin Boosts Survival for Breast Cancer, Study Reports
Taking drug in addition to chemotherapy also reduces risk of cancer recurrence (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 21, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Trastuzumab (Herceptin) Continues to Show Life-Altering Benefit
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit  JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. They found that the use of [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - October 21, 2014 Category: Hospital Management Source Type: news

Herceptin Boosts Survival for Breast Cancer, Study Reports
Taking drug in addition to chemotherapy also reduces risk of cancer recurrence (Source: WebMD Health)
Source: WebMD Health - October 20, 2014 Category: Consumer Health News Source Type: news

Herceptin Boosts Survival for Breast Cancer, Study Reports
Taking drug in addition to chemotherapy also reduces risk of cancer recurrence Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 20, 2014 Category: Consumer Health News Source Type: news

Trastuzumab continues to show life for HER2-positve early stage breast cancer
(Mayo Clinic) After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news

Green tea compound may improve cancer drugs
Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results f...
Source: NHS News Feed - October 6, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Study Shows Roche's Perjeta Extended Lives of Breast Cancer Patients by 15.7 Months
Adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 30, 2014 Category: Pharmaceuticals Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Title: Herceptin Best for Certain Breast Cancer Patients, Study SaysCategory: Health NewsCreated: 9/30/2014 9:35:00 AMLast Editorial Review: 9/30/2014 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 30, 2014 Category: Cancer & Oncology Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - September 30, 2014 Category: Cancer & Oncology Source Type: news

New breast cancer drug cocktail shows 'unprecedented' boost to patient's lifespan
Patients given a cocktail of two drugs by Swiss firm Roche lived 15.7 months longer than those on Herceptin and chemotherapy alone. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests
Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2014 Category: Science Source Type: news

Hopes for new breast cancer drug
A breast cancer drug could extend the lives of patients with an advanced form of the disease by almost five years, a study has found.Women with an aggressive type of cancer which has been traditionally hard to treat could benefit from using perjeta as a combination therapy with chemotherapy and herceptin, researchers said.A trial into the effectiveness of the combination of drugs found that survival among women with previously untreated advanced HER2-positive breast cancer was e (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - September 29, 2014 Category: Nursing Source Type: news

Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
(Mayo Clinic) Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2014 Category: Cancer & Oncology Source Type: news

'Unprecedented' Survival of 15 Months Seen in CLEOPATRA'Unprecedented' Survival of 15 Months Seen in CLEOPATRA
Pertuzumab plus trastuzumab adds a 15-month survival benefit in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

16 Months' Longer Survival with Addition of Pertuzumab in Advanced Breast Cancer (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding pertuzumab (Perjeta) to docetaxel and trastuzumab (Herceptin) as a first-line treatment was associated with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 29, 2014 Category: Primary Care Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2014 Category: Science Source Type: news

Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Media News)
Source: Roche Media News - September 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
(European Society for Medical Oncology) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 28, 2014 Category: Biology Source Type: news

HER2 in Trastuzumab/Emtansine vs Trastuzumab/DocetaxelHER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel
What group of patients experience enhanced improvement from T-DM1 therapy? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 5, 2014 Category: Science Source Type: news

Cardiovascular Toxicity Associated With Adjuvant TrastuzumabCardiovascular Toxicity Associated With Adjuvant Trastuzumab
Who is at risk for cardiac toxicity associated with trastuzumab? How should patients be screened? Therapeutic Advances in Drug Safety (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 21, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Merrimack begins Phase II HERMIONE trial of MM-302 for breast cancer treatment
US-based Merrimack Pharmaceuticals has started the Phase II HERMIONE trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin) to treat patients with HER2-positive locally advanced or met… (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2014 Category: Pharmaceuticals Source Type: news

NICE rejects Roche’s new breast cancer drug over high pricing
The NHS drug advisory body National Institute for Health and Care Excellence (NICE) has rejected Roche’s new breast cancer drug Kadcyla (trastuzumab emtansine) because of the treatment's high cost. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 10, 2014 Category: Pharmaceuticals Source Type: news

'Revolutionary' breast cancer drug denied on NHS over cost: Nice
A 'revolutionary' breast cancer drug that can give patients an extra six months of life has been turned down by the NHS drugs rationing body as it is too expensive (Source: Telegraph Health)
Source: Telegraph Health - August 8, 2014 Category: Consumer Health News Tags: rastuzumab emtansine breakthrough breast cancer Herceptin Nice her 2 Source Type: news

[Research Article] MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer
Activating a deacetylase may overcome resistance to a receptor-targeted inhibitor in some breast cancer patients. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - July 30, 2014 Category: Science Authors: Umadevi Thirumurthi, Jia Shen, Weiya Xia, Adam M. LaBaff, Yongkun Wei, Chia-Wei Li, Wei-Chao Chang, Chung-Hsuan Chen, Hui-Kuan Lin, Dihua Yu, Mien-Chie Hung Source Type: news

Aggressive breast cancer protein discovered
Conclusion This is a valuable laboratory study that furthers our understanding of the way HER2 may promote the growth, proliferation and spread of breast cancer cells, possibly through the influence of the protein integrin αvβ6. The researchers suggest up to 40% of people with HER2-positive breast cancers may also have a high expression of integrin αvβ6. The discovery that integrin αvβ6 may play a role in mediating the growth and progression of these cancers hopefully opens up new treatment possibilities for people with HER2-positive cancers. As the researchers suggest, their study supports...
Source: NHS News Feed - July 7, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news